Use of Pegylated IL-10 to Treat Cancer

• US 20080081031A1
• Filed: 09/27/2007
• Published: 04/03/2008
• Est. Priority Date: 09/28/2006
• Status: Abandoned Application

• Current Assignee: Schering Corporation (Merck & Co., Inc.)
• Original Assignee: Schering Corporation (Merck & Co., Inc.)
• Inventors: Oft, Martin, Sheppard, Catherine, Mumm, John
• Application Number:
  US11/862,626
• Publication Number:
  US 20080081031A1
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/3015 Breast
• CPC Class Codes: C07K 16/3023 Lung
• CPC Class Codes: C07K 16/3046 Stomach, Intestines
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.

Claims

1. A method of inhibiting or reducing growth of a tumor or cancer comprising contacting the tumor with an effective amount of a pegylated interleukin-10 (PEG-IL-10).

2. The method of claim 1, wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

3. The method of claim 1, wherein the PEG-IL-10 inhibits growth of the tumor or cancer.

4. The method of claim 1, wherein the PEG-IL-10 reduces the size of the tumor or cancer.

5. The method of claim 1, wherein PEG-IL-10 increases infiltration of CD8+ T cells into the tumor when compared to non-pegylated IL-10.

6. The method of claim 1, wherein PEG-IL-10 increases the expression of at least one inflammatory cytokine.

7. The method of claim 6, wherein the inflammatory cytokine is selected from the group consisting of IFNγ

, IL-4, IL-6, IL-10, and RANK-ligand (RANK-L).

8. The method of claim 1, wherein the PEG-IL-10 is co-administered with at least one chemotherapeutic agent.

9. The method of claim 8, wherein the chemotherapeutic agent is at least one of the chemotherapeutic agents of Table 16.

10. The method of claim 1, wherein the tumor or cancer is selected from the group consisting of colon cancer, ovarian cancer, breast cancer, melanoma, lung cancer, glioblastoma, and leukemia.

11. A method of treating a subject suffering from a cancer or tumor comprising administering to the subject an effective amount of PEG-IL-10.

12. The method of claim 11, wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

13. The method of claim 11, wherein the PEG-IL-10 inhibits growth of the cancer or tumor.

14. The method of claim 11, wherein the PEG-IL-10 reduces the size of the tumor or cancer.

15. The method of claim 11, wherein PEG-IL-10 increases infiltration of CD8+ T cells into the tumor when compared to non-pegylated IL-10.

16. The method of claim 11, wherein PEG-IL-10 increases the expression of at least one inflammatory cytokine.

17. The method of claim 16, wherein the inflammatory cytokine is selected from the group consisting of IFNγ

, IL-4, IL-6, IL-10, and RANK-L.

18. The method of claim 11, wherein the PEG-IL-10 is co-administered with at least one chemotherapeutic agent.

19. The method of claim 18, wherein the chemotherapeutic agent is at least one of the chemotherapeutic agents of Table 16.

20. The method of claim 11, wherein PEG-IL-10 reduces metastasis of a cancer or tumor.

21. The method of claim 11, wherein the tumor or cancer is selected from the group consisting of colon cancer, ovarian cancer, breast cancer, lung cancer, melanoma, glioblastoma, and leukemia.

22. The method of claim 11, wherein the subject is human.

23. The method of claim 22, wherein the PEG-IL-10 is human PEG-IL-10 (PEG-hIL-10).